1. Scrip
  2. >>Business

Graffinity/MyoContract: Two Problems, One Solution

 
• By Melanie Senior

By merging with Swiss product development group MyoContract, Germany's Graffinity addresses its two key issues at once: a lack of products, and poor prospects for a viable listing in its home market. Europe's industry needs more such deals, but making them happen isn't easy.

Heidelberg-based Graffinity Pharmaceuticals AG is the latest German biotech to use M&A to morph from a platform into a product company. Until a few weeks ago, Graffinity was a typical German biotech. Founded in 1998 at the height of the country's government-funded BioRegio program, the company was built on the back of a series of clever technologies designed to help others discover and develop drugs.

Since then, the platform technology model has fallen out of favor. Shifting priorities at Big Pharma customers, the commoditization of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

In Brief: Bavarian Nordic’s Board Votes For Private Equity Takeout

 
• By Joseph Haas

The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By Kevin Grogan

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By Andy Smith

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.